Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer

British Journal of Cancer

Volumn 103, Issue 9, 2010, Pages 1349-1355

  Conroy, T ^a   Yataghene Y ^b   Etienne, P L ^c   Michel, P ^d   Senellart, H ^e   Raoul, J L ^f   Mineur, L ^g   Rives, M ^h   Mirabel, X ⁱ   Lamezec, B ^c   Rio, E ^e   Le Prise E ^j   Peiffert, D ^a   Adenis, A ⁱ  

^a CENTRE ALEXIS VAUTRIN   (France)

^b SANOFI   (France)

^c Clinique Armoricaine de Radiologie   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f UNIVERSITÉ DE RENNES 1   (France)

^g INSTITUT SAINTE CATHERINE   (France)

^h INSTITUT CLAUDIUS REGAUD   (France)

ⁱ CENTRE OSCAR LAMBRET   (France)

^j CENTRE EUGÈNE MARQUIS   (France)

more..

Author keywords

chemoradiotherapy; oesophageal cancer; oxaliplatin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGUS CANCER; ESOPHAGUS PAIN; FATIGUE; FEBRILE BONE MARROW APLASIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOCALCEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ODYNOPHAGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 78049279299     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605943     Document Type: Article

References (27)

1. Adelstein DJ, Rice TW, Becker M, Larto MA, Kirby TJ, Koka A, Tefft M, Zuccaro G (1997) Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80: 1011-1020
2. Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1: 277-284
3. American Cancer Society (2008) Cancer Facts & Figures. Atlanta: American Cancer Society.
4. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 350: 2343-2351.
5. Bedenne L, Seitz JF, Milan C, Renard P, Fraisse J, Conroy T, Lacourt J, Janoray P, Faivre J (1998) Cisplatine, 5-FU et radiothérapie préopératoire dans les cancers épidermö?des de l'œsophage. Gastroenterol Clin Biol 22: 273-281
6. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM (2004) Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 91: 199-204
7. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE (2000) Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 18: 455-462
8. Conroy T, Viret F, François E, Seitz JF, Boige V, Ducreux M, Ychou M, Metges JP, Giovannini M, Yataghene Y, Peiffert D (2008) Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer. Br J Cancer 99: 1395-1401
9. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up a prospective randomized trial (RTOG 85-01). JAMA 281: 1623-1627
10. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
11. Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P (2007) Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 102: 2557-2563
12. Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C (1992) Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 10: 1037-1043
13. Kalha I, Kaw M, Fukami N, Patel M, Singh S, Gagneja H, Cohen D, Morris J(2004) The accuracy of endoscopic ultrasound for restaging esophagealcarcinoma after chemoradiation therapy. Cancer 101: 940-947
14. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844-2850
15. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold OJ, Corless CL (2009) Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adeno-carcinoma (EA): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol 27: 15s (suppl): abstract 4513
16. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE(2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil inpatients with advanced carcinoma of the esophagus. Ann Oncol 16:1320-1325
17. Minsky BD, Pajack TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167-1174
18. O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM (2007) Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer 13: 119-124
19. Poplin E, Fleming T, Leichman L, Seydel HG, Steiger Z, Taylor S, Vance R, Stuckey WJ, Rivkin SE (1987) Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group study (SWOG-8037). J Clin Oncol 5: 622-628
20. Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW (2009) Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg 249: 764-767
21. Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH (2008) Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 248: 902-908
22. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S (2005) Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 35: 316-323
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
24. Thomas CR, Berkey BA, Minsky BD, Gaspar LE, Herskovic A, Rich TA, Gunderson LL (2004) Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 58: 1405-1410
25. Triboulet JP, Amrouni H, Guillem P, Vandenhaute B, Lecomte-Houcke M, Adenis A (1998) Devenir des cancers épidermö?des de l'œsophage en réponse complète après chimio-radiothérapie pré-opératoire. Ann Chir 52: 503-508
26. Vogel SB, Mendelhall WB, Sombeck MD, Marsh R, Woodward ER (1995) Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 221: 685-693
27. Westerterp M, van Westreenen HL, Reitsma JB, R Ansari H, Kasza K, Szeto L, Vokes EE (2005) Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236: 841-851